Medicus Pharma Ltd SEC Filings

Schedule 13G/A disclosure: This filing reports beneficial ownership in Medicus Pharma Ltd. by Dr. Kenneth Melani and Velocity Fund Partners, LP. Dr. Kenneth Melani directly holds 409,411 common shares. Velocity Fund Partners, LP directly holds 2,839,330 common shares, and the two Reporting Persons together report an aggregate beneficial ownership of 3,248,741 shares, representing 18.2% of the outstanding class. The Velocity position alone is reported as 2,839,330 shares (15.9%).

The cover-page entries state sole voting power and sole dispositive power of 3,248,741 shares for Dr. Melani and of 2,839,330 shares for Velocity Fund Partners. The percentages are calculated using 17,816,266 shares outstanding as reported by the Company in its Quarterly Report. The filing also notes that Dr. Melani "may be deemed" the beneficial owner of securities held by Velocity but expressly disclaims beneficial ownership except to the extent of his direct holdings. Exhibit 99.1 (Joint Filing Agreement) is incorporated by reference.

Medicus Pharma Ltd. Schedule 13G/A reports that SkinJect Partners LLC directly owns 800,952 common shares of Medicus Pharma, representing 4.5% of the outstanding common stock based on 17,816,266 shares reported by the company. The filing shows SkinJect Partners has sole voting and sole dispositive power over these shares.

John Hathaway is identified as a reporting person and may be deemed the beneficial owner of the shares held by SkinJect Partners LLC, though he disclaims beneficial ownership except to the extent of any direct ownership. The filing provides standard disclosure of ownership and power to vote or dispose.

Medicus Pharma Ltd. (MDCX) is a clinical-stage life sciences company focused on advancing a dissolvable doxorubicin microneedle array program (SkinJect) and opportunistic biotech acquisitions. The company reported $9,669,546 in cash and cash equivalents at June 30, 2025, up from $4,164,323 at year-end 2024, driven by equity offerings and warrant exercises.

Operating losses widened: a six-month net loss of $11,278,492 in 2025 versus $5,340,217 in 2024, producing an accumulated deficit of $40,182,395. Cash used in operations was $9,409,825 for the six months. The company closed a $4.17M Regulation A offering and a $7.01M June 2025 public offering, issued debentures for $4.5M (principal $5.0M) and entered a SEPA commitment for up to $15M. The company also agreed to acquire Antev Limited for consideration shares and contingent payments up to $65M. Management discloses substantial doubt about going concern and identified material weaknesses in internal controls.

On 4 Aug 2025 Medicus Pharma (MDCX) filed an 8-K announcing a non-binding Memorandum of Understanding (MoU) with Boston-based Helix Nanotechnologies. The parties intend to merge HelixNano’s proprietary mRNA vaccine platform with Medicus’ microneedle array (MNA) delivery technology to create thermostable, needle-free vaccines for infectious diseases.

The MoU outlines: (i) good-faith negotiations to form a joint venture for co-development and commercialisation; and (ii) an immediate collaborative project to manufacture clinical-grade MNA-loaded doses of HelixNano’s candidate HN-0001 for a Phase 1 bridging study comparing intramuscular versus intradermal delivery. Except for limited sections, the MoU is expressly non-binding; either party may withdraw until definitive agreements are executed. No financial terms, milestones, equity allocations or timelines were disclosed, and the filing contains no revenue or earnings data. A press release (Exhibit 99.1) accompanies the report, while Item 9.01 lists standard exhibit references.